C2N Diagnostics, LLC
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From C2N Diagnostics, LLC
ADDF’s Fillit On FDA’s Tough Aducanumab Decision, Advances In Alzheimer’s
The pending US FDA decision on Biogen’s drug overshadows progress in Alzheimer’s diagnosis, symptomatic treatments and the need to keep studying anti-tau therapies after Roche’s setback.
AbbVie’s Five Biggest Priorities, Apart From Allergan
While it works on merging with Allergan, AbbVie is tracking biosimilar sales erosion to Humira, the promising launch of Skyrizi and the growth of Imbruvica and Venclexta. It is terminating a Phase II study of a tau-targeting antibody and worried about aspects of the Senate drug pricing bill.
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Biogen agreed to pay $300m upfront to buy a Phase II-ready tau antibody from Bristol. The plan is to move rapidly into mid-stage clinical trials for Alzheimer's disease and progressive supranuclear palsy.
Pipeline Watch: Phase III Trials For Daprodustat, Rovalpituzumab Tesirine
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
In Vitro Diagnostics
- Chemistry, Immunoassay
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.